Stock Price
15.48
Daily Change
0.06 0.39%
Monthly
-1.02%
Yearly
86.51%
Q1 Forecast
14.88

Amarin reported $-7.74M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amarin USD -7.74M 6.4M Sep/2025
AstraZeneca USD 2.33B 207M Dec/2025
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025